2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Sell
48
VRNA Quote, Financials, Valuation and Earnings
Last price:
$66.64
Seasonality move
:
-2.49%
Day range:
$61.34 - $64.44
52-week range:
$11.39 - $70.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
25.50x
Volume:
2.3M
Avg. volume:
1.5M
1-year change:
295.05%
Market cap:
$5.2B
Revenue:
$42.3M
EPS (TTM):
-$2.16
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$33.5M | -$0.15 | -- | -89.84% | $81.00 |
|
BCYC
Bicycle Therapeutics PLC
|
$5.5M | -$0.85 | -55.59% | -31.65% | $29.55 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$0.01 | 1109.31% | -69.36% | $7.89 |
|
NCNA
NuCana PLC
|
-- | -$2.20 | -- | -98.11% | $64.50 |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$61.39 | $81.00 | $5.2B | -- | $0.00 | 0% | -- |
|
BCYC
Bicycle Therapeutics PLC
|
$9.65 | $29.55 | $667.8M | -- | $0.00 | 0% | 15.91x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.90 | $17.97 | $1.3M | -- | $0.00 | 0% | 1.71x |
|
MREO
Mereo BioPharma Group PLC
|
$2.62 | $7.89 | $406.5M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.76 | $64.50 | $3M | -- | $0.00 | 0% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
$1.73 | -- | $887.5K | -- | $0.25 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
37.04% | -0.759 | 3.06% | 10.24x |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 0.789 | -- | 13.61x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 0.756 | -- | 1.20x |
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.564 | -- | -- |
|
NCNA
NuCana PLC
|
-- | 0.645 | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -1.548 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$67.1M | -25.48% | -26.21% | -1426.21% | -$9.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$9.1M | -- | -- | -- | -$7.5M |
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
Verona Pharma PLC vs. Competitors
-
Which has Higher Returns VRNA or BCYC?
Bicycle Therapeutics PLC has a net margin of -92.29% compared to Verona Pharma PLC's net margin of -1398.44%. Verona Pharma PLC's return on equity of -88.7% beat Bicycle Therapeutics PLC's return on equity of -26.21%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC94.44% -$0.40 $324.9M BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M -
What do Analysts Say About VRNA or BCYC?
Verona Pharma PLC has a consensus price target of $81.00, signalling upside risk potential of 31.94%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $29.55 which suggests that it could grow by 206.17%. Given that Bicycle Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 BCYCBicycle Therapeutics PLC5 3 0 -
Is VRNA or BCYC More Risky?
Verona Pharma PLC has a beta of 0.392, which suggesting that the stock is 60.803% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.137%.
-
Which is a Better Dividend Stock VRNA or BCYC?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or BCYC?
Verona Pharma PLC quarterly revenues are $36.7M, which are larger than Bicycle Therapeutics PLC quarterly revenues of $3.7M. Verona Pharma PLC's net income of -$33.8M is higher than Bicycle Therapeutics PLC's net income of -$51.9M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus 15.91x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $36.7M -$33.8M BCYCBicycle Therapeutics PLC15.91x -- $3.7M -$51.9M
-
Which has Higher Returns VRNA or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -92.29% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -88.7% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC94.44% -$0.40 $324.9M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About VRNA or BDRX?
Verona Pharma PLC has a consensus price target of $81.00, signalling upside risk potential of 31.94%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 852.19%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Verona Pharma PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is VRNA or BDRX More Risky?
Verona Pharma PLC has a beta of 0.392, which suggesting that the stock is 60.803% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.
-
Which is a Better Dividend Stock VRNA or BDRX?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or BDRX?
Verona Pharma PLC quarterly revenues are $36.7M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Verona Pharma PLC's net income of -$33.8M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus 1.71x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $36.7M -$33.8M BDRXBiodexa Pharmaceuticals PLC1.71x -- -- --
-
Which has Higher Returns VRNA or MREO?
Mereo BioPharma Group PLC has a net margin of -92.29% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -88.7% beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC94.44% -$0.40 $324.9M MREOMereo BioPharma Group PLC-- -$0.10 -- -
What do Analysts Say About VRNA or MREO?
Verona Pharma PLC has a consensus price target of $81.00, signalling upside risk potential of 31.94%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.89 which suggests that it could grow by 201.16%. Given that Mereo BioPharma Group PLC has higher upside potential than Verona Pharma PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 MREOMereo BioPharma Group PLC6 0 0 -
Is VRNA or MREO More Risky?
Verona Pharma PLC has a beta of 0.392, which suggesting that the stock is 60.803% less volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.723%.
-
Which is a Better Dividend Stock VRNA or MREO?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or MREO?
Verona Pharma PLC quarterly revenues are $36.7M, which are larger than Mereo BioPharma Group PLC quarterly revenues of --. Verona Pharma PLC's net income of -$33.8M is lower than Mereo BioPharma Group PLC's net income of -$15M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $36.7M -$33.8M MREOMereo BioPharma Group PLC-- -- -- -$15M
-
Which has Higher Returns VRNA or NCNA?
NuCana PLC has a net margin of -92.29% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -88.7% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC94.44% -$0.40 $324.9M NCNANuCana PLC-- -$2.28 -- -
What do Analysts Say About VRNA or NCNA?
Verona Pharma PLC has a consensus price target of $81.00, signalling upside risk potential of 31.94%. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 8381.26%. Given that NuCana PLC has higher upside potential than Verona Pharma PLC, analysts believe NuCana PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 NCNANuCana PLC1 1 0 -
Is VRNA or NCNA More Risky?
Verona Pharma PLC has a beta of 0.392, which suggesting that the stock is 60.803% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.789%.
-
Which is a Better Dividend Stock VRNA or NCNA?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or NCNA?
Verona Pharma PLC quarterly revenues are $36.7M, which are larger than NuCana PLC quarterly revenues of --. Verona Pharma PLC's net income of -$33.8M is lower than NuCana PLC's net income of -$5.9M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $36.7M -$33.8M NCNANuCana PLC-- -- -- -$5.9M
-
Which has Higher Returns VRNA or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -92.29% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -88.7% beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC94.44% -$0.40 $324.9M TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About VRNA or TCBP?
Verona Pharma PLC has a consensus price target of $81.00, signalling upside risk potential of 31.94%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 2674.57%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Verona Pharma PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is VRNA or TCBP More Risky?
Verona Pharma PLC has a beta of 0.392, which suggesting that the stock is 60.803% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock VRNA or TCBP?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. Verona Pharma PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or TCBP?
Verona Pharma PLC quarterly revenues are $36.7M, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. Verona Pharma PLC's net income of -$33.8M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $36.7M -$33.8M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Is Goldman Sachs Stock a Buy Sell or Hold?
When the Federal Reserve started hiking rates in 2022, banks’…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
49
SMTC alert for Mar 17
Semtech [SMTC] is down 0.49% over the past day.
Buy
62
PLPC alert for Mar 17
Preformed Line Products [PLPC] is up 3.8% over the past day.
Sell
50
NUTX alert for Mar 17
Nutex Health [NUTX] is up 4.82% over the past day.
